Literature DB >> 22067048

Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship between AMD and atherosclerosis.

Anna Machalińska1, Miłosz P Kawa, Wojciech Marlicz, Bogusław Machaliński.   

Abstract

Age-related macular degeneration (AMD) shares several pathological and epidemiological similarities with systemic atherosclerosis (AS). First, an association between AS and AMD is apparent from the analyses of the histological and biochemical structure of atherosclerotic plaques in the vascular walls and retinal drusen, the hallmark of AMD. Second, there is considerable evidence implicating endothelial dysfunction in the pathogenesis of both disorders, and cellular oxidative stress appears to be a common denominator underlying this process. Moreover, there are observations that the complement system (CS) triggering inflammatory response contributes to the onset and advancement of both diseases. The CS plays a role in the generation of drusen and neovascularization in AMD as well as in vascular endothelium activation, cell damage and ultimately atherosclerotic plaque formation in the course of systemic arteriosclerosis. It is widely recognized that both AMD and AS are not only related to local stimulation of the CS, but also result in its systemic activation. In addition, a specific Y402H polymorphism of the complement inhibitor factor H has been found to be associated with the incidence of both AMD and AS. Here, we propose a linking hypothesis between CS activation, endothelial dysfunction and the pathogenesis of two common and age-related pathological processes, AS and AMD. We also discuss the potential therapeutic value of pharmacological modulation of CS activation in these disorders.
© 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067048     DOI: 10.1111/j.1755-3768.2011.02295.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  29 in total

1.  The relationship between vascular endothelial dysfunction and treatment frequency in neovascular age-related macular degeneration.

Authors:  Tomoko Ueda-Consolvo; Atsushi Hayashi; Mayumi Ozaki; Tomoko Nakamura; Takaaki Yagou; Shinya Abe
Journal:  Jpn J Ophthalmol       Date:  2017-04-26       Impact factor: 2.447

2.  Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008.

Authors:  D T Q Barbosa; T S Mendes; H R Cíntron-Colon; S Y Wang; R B Bhisitkul; K Singh; S C Lin
Journal:  Eye (Lond)       Date:  2014-02-07       Impact factor: 3.775

3.  Playing 'hide-and-seek' with factor H: game-theoretical analysis of a single nucleotide polymorphism.

Authors:  Sabine Hummert; Christina Glock; Stefan N Lang; Christian Hummert; Christine Skerka; Peter F Zipfel; Sebastian Germerodt; Stefan Schuster
Journal:  J R Soc Interface       Date:  2018-05       Impact factor: 4.118

4.  Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Chelsea E Myers; Karen J Cruickshanks; Ronald E Gangnon; Lorraine G Danforth; Theru A Sivakumaran; Sudha K Iyengar; Michael Y Tsai; Barbara E K Klein
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

Review 5.  Nanoengineering of therapeutics for retinal vascular disease.

Authors:  Nivriti Gahlaut; Sandra Suarez; Md Imam Uddin; Andrew Y Gordon; Stephanie M Evans; Ashwath Jayagopal
Journal:  Eur J Pharm Biopharm       Date:  2015-05-28       Impact factor: 5.571

6.  Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratio with visual acuity and macular thickness in age-related macular degeneration.

Authors:  Elvan Alper Sengul; Ozgur Artunay; Alev Kockar; Ceyda Afacan; Rifat Rasier; Palmet Gun; Nazli Gul Yalcin; Erdal Yuzbasioglu
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

7.  C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.

Authors:  Saif Ahmad; Chirayu Pandya; Adam Kindelin; Kanchan Bhatia; Rafay Chaudhary; Alok Kumar Dwivedi; Jennifer M Eschbacher; Qiang Liu; Michael F Waters; Md Nasrul Hoda; Andrew F Ducruet
Journal:  Br J Pharmacol       Date:  2020-03-04       Impact factor: 8.739

Review 8.  Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration.

Authors:  Deborah A Ferrington; Debasish Sinha; Kai Kaarniranta
Journal:  Prog Retin Eye Res       Date:  2015-09-04       Impact factor: 21.198

9.  Alterations of choroidal blood flow regulation in young healthy subjects with complement factor H polymorphism.

Authors:  Reinhard Told; Stefan Palkovits; Helmuth Haslacher; Sophie Frantal; Doreen Schmidl; Agnes Boltz; Michael Lasta; Semira Kaya; René M Werkmeister; Gerhard Garhöfer; Leopold Schmetterer
Journal:  PLoS One       Date:  2013-04-15       Impact factor: 3.240

10.  Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.

Authors:  Christoph Q Schmidt; Hongjun Bai; Zhuoer Lin; Antonio M Risitano; Paul N Barlow; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.